Therefore, targeting both estrogen signaling with selective estrogen receptor modulators (e.g., tamoxifen) 41 and estrogen biosynthesis with aromatase inhibitors (e.g., letrozole) 42 may offer a viable therapeutic strategy, given their established efficacy in estrogen-related neoplasms. Here, CYP19A1 is linked to neoplasm.